CHT101 for CD70-positive advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer is advanced or has spread, and standard treatments have stopped working or caused severe side effects.
- Your tumor cells have a protein called CD70 on their surface (a test will confirm this).
- You have at least one tumor that can be seen on a CT scan or MRI.
- Your general health is good (ECOG score 0 or 1, meaning you can do most daily activities).
- Your liver, kidneys, and blood counts are working well enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, CHT101, for people with certain blood cancers that have not responded to prior treatments. It is specifically for cancers that test positive for a protein called CD70.
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new treatment called CHT102 for people with advanced pancreatic cancer that has a specific protein (mesothelin) on their tumor cells. It's for those who have already tried standard treatments without success or couldn't tolerate them.
Hear when a new Relapsed / Refractory Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.